Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2000
09/28/2000WO2000022142A3 Cell signaling polypeptides and nucleic acids
09/28/2000WO2000020576A3 Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
09/28/2000WO2000020447A3 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
09/28/2000WO2000018796A3 Secretory protein- zsig48
09/28/2000WO2000015793A3 Human gpcr proteins
09/28/2000WO2000013712A3 Methods and compositions for the prevention or treatment of cancer
09/28/2000WO2000000483A3 Tubulin binding compounds (cobra)
09/28/2000DE19913692A1 Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen Mechanically stable pharmaceutical dosage forms containing liquid or semisolid surface-active substances
09/28/2000DE19913333A1 Use of hyperforin for treating cancer, or in topical compositions optionally together with hypericin for treating e.g. inflammatory skin disease, skin aging or bacterial skin infections
09/28/2000DE19911771A1 Neue LHRH-Antagonisten mit verbesserten Löslichkeitseigenschaften New LHRH antagonists with improved solubility
09/28/2000CA2855415A1 Phenylalanine derivatives
09/28/2000CA2669512A1 Human antibodies that bind human il-12 and methods for producing
09/28/2000CA2377383A1 Apoptosis related genes
09/28/2000CA2371990A1 Use of stabilised oligonucleotides for preparing a medicine with antitumour activity
09/28/2000CA2368733A1 Phenylalanine derivatives
09/28/2000CA2368229A1 50 human secreted proteins
09/28/2000CA2368210A1 50 human secreted proteins
09/28/2000CA2368047A1 Chemokine receptor binding heterocyclic compounds
09/28/2000CA2368041A1 Indolinone compounds as kinase inhibitors
09/28/2000CA2367963A1 Hydroxamic and carboxylic acid derivatives
09/28/2000CA2367866A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000CA2367861A1 Quinazolines and therapeutic use thereof
09/28/2000CA2367857A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
09/28/2000CA2367699A1 Inflammatory mediation obtained from atractylodes lancea
09/28/2000CA2367620A1 47 human secreted proteins
09/28/2000CA2367488A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
09/28/2000CA2367471A1 Fungal beta-tubulin genes
09/28/2000CA2367464A1 Materials and methods relating to modulation of p66 expression
09/28/2000CA2367282A1 Pharmaceutical compositions comprising metal complexes
09/28/2000CA2367262A1 Treatment of immune diseases
09/28/2000CA2367045A1 Treatment of certain cancers associated with weight gain
09/28/2000CA2366998A1 Quinazoline formulations and therapeutic use thereof
09/28/2000CA2366877A1 Chemical compounds and their uses
09/28/2000CA2366691A1 48 human secreted proteins
09/28/2000CA2366650A1 Oral low dose butyrate compositions
09/28/2000CA2366267A1 49 human secreted proteins
09/28/2000CA2366214A1 Dsp-2 dual-specificity map kinase phosphatase
09/28/2000CA2365405A1 Human tumor necrosis factor receptor-like 2
09/28/2000CA2365255A1 Human tumor necrosis factor receptor tr9
09/28/2000CA2365247A1 49 human secreted proteins
09/28/2000CA2365244A1 Calanolides for inhibiting btk
09/28/2000CA2365243A1 Human transmembrane proteins
09/28/2000CA2365238A1 48 human secreted proteins
09/28/2000CA2365223A1 46 human secreted proteins
09/28/2000CA2365201A1 Organic-arsenic compounds
09/28/2000CA2365121A1 Antibodies specific for cyp1b1
09/28/2000CA2365104A1 Anti-p53 antibodies
09/28/2000CA2365081A1 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
09/28/2000CA2362705A1 N-adamant-1-yl-n'-¬4-chlorobenzothiazol-2-yl| urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
09/28/2000CA2362380A1 Amino-thio-acrylonitriles as mek inhibitors
09/28/2000CA2361221A1 Novel protein which induces chondrocyte differentiation
09/28/2000CA2361055A1 Viral agents
09/28/2000CA2356816A1 Inhibitors of the egf-receptor tyrosine kinase and their use
09/27/2000EP1038952A2 Processes for preparation of Marek's Disease Virus using continuous avian cell lines
09/27/2000EP1038863A2 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof
09/27/2000EP1038530A2 Immunomodulator comprising DNA
09/27/2000EP1038528A1 Pentosan polysulfate containing medicament and implant for treating fibrosis
09/27/2000EP1038523A2 Method for identifying compounds for inhibition of neoplastic lesions
09/27/2000EP1038027A1 Decreasing cell proliferation by decreasing levels of pp5
09/27/2000EP1038025A1 Genetic alterations associated with cancer
09/27/2000EP1038016A2 Needle-free injection of formulated nucleic acid molecules
09/27/2000EP1038011A2 Methods of producing anti-angiogenic proteins; endostatin, angiostatin or restin, using a pichia yeast expression system
09/27/2000EP1038003A1 Cyclic gmp phosphodiesterase
09/27/2000EP1038002A1 Ubiquitin-like conjugating protein
09/27/2000EP1037995A1 Human interferon-epsilon: a type 1 interferon
09/27/2000EP1037994A1 Peptide antagonists of vascular endothelial growth factor
09/27/2000EP1037989A2 Nucleotide and protein sequence of mammastatin and methods of use
09/27/2000EP1037985A1 Restin and methods of use thereof
09/27/2000EP1037983A1 Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
09/27/2000EP1037981A1 Soluble inhibitors of vascular endothelial growth factor and use thereof
09/27/2000EP1037980A1 G-protein coupled receptors associated with immune response
09/27/2000EP1037970A1 Secreted proteins and polynucleotides encoding them
09/27/2000EP1037967A2 Human phosphatases
09/27/2000EP1037926A1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES
09/27/2000EP1037919A1 Proteins for cancer cell specific induction of apoptosis and method for isolation thereof
09/27/2000EP1037915A1 Matrix-remodeling genes
09/27/2000EP1037908A2 Human tumor necrosis factor-r2-like proteins
09/27/2000EP1037901A1 Mammaglobin, a secreted mammary-specific breast cancer protein
09/27/2000EP1037898A1 Secreted proteins
09/27/2000EP1037886A1 Triazine angiogenesis inhibitors
09/27/2000EP1037883A1 NOVEL HETEROCYCLICALLY SUBSTITUTED $g(a)-HYDROXYCARBOXLIC ACID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
09/27/2000EP1037868A2 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
09/27/2000EP1037670A2 Agent for gene therapy of tumor, neurodegenerative, cardiovascular and autoimmune diseases
09/27/2000EP1037665A1 Methods and compositions for inhibiting tumor cell growth
09/27/2000EP1037658A1 Ifnar2/ifn complex
09/27/2000EP1037655A2 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
09/27/2000EP1037636A1 Inhibition of membrane-associated viral replication
09/27/2000EP1037629A2 Combination of a retinoic acid metabolism blocking agent and a tocophereol
09/27/2000EP1037626A1 Multicatalytic protease inhibitors for use as anti-tumor agents
09/27/2000EP1037625A1 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
09/27/2000EP1037610A1 Liposomal camptothecin formulations
09/27/2000EP1037534A1 A fagopyrum cymosum (trev.) meisn composition, method to prepare and analyze the same and uses thereof
09/27/2000EP1037529A1 Composition useful for providing one-step surgical preparation and drape
09/27/2000EP0688224B1 A mutant crp-protein and methods and materials for making and using it
09/27/2000CN1268140A Monocyclic L-nucleosides, analogs and uses thereof
09/27/2000CN1268134A Bis-indole derivatives having antimetastatic activity, A process for their preparation and pharmaceutical compositions containing them
09/27/2000CN1268133A 2-Aminopyridines containing fused ring substituents as NOS inhibitors
09/27/2000CN1268122A Branched alkoxy- substituted 2-aminopyridines as NOS inhibitors
09/27/2000CN1268061A Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
09/27/2000CN1267723A Saffron polyploid cell culture process to produce crosin and similar active matter
1 ... 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 ... 2211